Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Phase 2

Genetic TestingTargeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Sponsor:

National Cancer Institute (NCI)

Code:

NCT03155620

Conditions

Advanced Malignant Solid Neoplasm

Ann Arbor Stage III Non-Hodgkin Lymphoma

Ann Arbor Stage IV Non-Hodgkin Lymphoma

Histiocytic Sarcoma

Juvenile Xanthogranuloma

Eligibility Criteria

Sex: All

Age: 12 - 21

Healthy Volunteers: Not accepted

Interventions

Biopsy Procedure

Biospecimen Collection

Bone Marrow Aspiration and Biopsy

Bone Scan

Computed Tomography

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-04-09.